Licensing, Pharmacy and Webinar - Drug Discovery Digest

Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

FEBRUARY 26, 2025

Pharmacies and Pharmacy Benefit Managers. Email Paula Fein ( paula@drugchannels.net ) if youd like to bundle the report purchase with access to DCIs video webinars. On March 18, 2025, Drug Channels Institute will release The 2025 Economic Report on U.S. drug pricing, reimbursement, and dispensing system.

Pharmacy

Pharmacy Licensing Licensing Drugs

Redefining commercial success in specialty lite with alternative channels

BioPharma Drive: Drug Pricing

JULY 28, 2025

Unsuitable for standard retail yet not requiring the full infrastructure of specialty pharmacies, these products face unique access barriers that traditional distribution models cant address effectively. Alternative channels that bring together tech-driven hub services and integrated pharmacy networks to maximize profitable revenue growth.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Clinical Trials Therapies

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

BioPharma Drive: Drug Pricing

AUGUST 11, 2025

11, 2025 post share post print email shutterstock.com/ PeopleImages.com - Yuri A Sponsored content By GoodRx SPONSORED CONTENT BY While direct-to-consumer (DTC) advertising is effective at top-of-funnel awareness and driving action early in the patient journey, it cannot pull through conversions at the pharmacy. Another paradox: while U.S.

Marketing

Marketing Pharmacy Therapies Clinical Trials

NOW AVAILABLE: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

MARCH 19, 2024

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers’ (press release) Review pricing/license options and download the full 2024 report We’re offering special discounted pricing if you order before April 8, 2024.

Pharmacy

Pharmacy Licensing Licensing Drugs

Available for Preorder: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

MARCH 7, 2024

Pharmacies and Pharmacy Benefit Managers. Review pricing/license options and place a preorder. Email Paula Fein ( paula@drugchannels.net ) if you’d like to bundle the report purchase with access to DCI’s video webinars. On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S.

Pharmacy

Pharmacy Licensing Licensing Drugs

Replimune drug rejected by FDA; Omega raises $647M biotech fund

BioPharma Drive: Drug Pricing

JULY 22, 2025

Published July 22, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed. and European life sciences companies.

FDA

FDA Specialty Pharmacies Drugs Therapies

NOW AVAILABLE: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

MARCH 18, 2025

Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! Pharmacies and Pharmacy Benefit Managers.

Pharmacy

Pharmacy Specialty Pharmacies Licensing Licensing

How Pharma-Funded Groups Lie About Personal Drug Imports

Policy Prescription

MAY 28, 2021

NeedyMeds , a non-profit organization known for providing patients with help in finding pharmaceutical company-sponsored prescription assistance programs and other drug savings options, hosted a webinar about drug importation last year called “ Drug Importation: The topic everyone’s talking about.” The featured speaker was, Shabbir J.

Pharmacy

Pharmacy Licensing Licensing Online Pharmacies

The Pharmacist in the Value-Based Care Era

Fierce BioTech

MARCH 29, 2024

Is your pharmacy ready to make the leap? Is your pharmacy ready to make the leap? Listing Image Inovalon Logo.png Listing Introduction Pharmacists are being called to operate at the top of their license to close gaps in care. Learn how your pharmacy can prepare today for a future of pharmacy focused on patient outcomes.

Pharmacy

Pharmacy Licensing Licensing Pharmaceuticals

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

BioPharma Drive: Drug Pricing

JULY 23, 2025

Published July 23, 2025 Ben Fidler Senior Editor post share post print email license The executive leadership team of Dispatch Bio, as well as scientific cofounder Carl June and board chair Jeff Marrazzo. Dispatch is led by CEO Sabah Oney, a venture partner at Arch who previously held executive positions at Alector and Ariosa Diagnostics.

Therapies

Therapies Specialty Pharmacies Pharmacy FDA

Apples to apples: Stelara biosimilars and the fight for market share

BioPharma Drive: Drug Pricing

JULY 21, 2025

In the Humira biosimilars competition, achieving FDA-approved interchangeability was a huge boon, as it meant that the biosimilar could be substituted for the originator drug at the pharmacy level, unlike its peers.

Biosimilars

Biosimilars Marketing FDA Therapies

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

OCTOBER 27, 2023

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA

FDA Science Regulations Production

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

BioPharma Drive: Drug Pricing

JULY 21, 2025

Published July 21, 2025 Ben Fidler Senior Editor Ned Pagliarulo Lead Editor post share post print email license Courtesy of Sarepta One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. Please select at least one newsletter. as Scientific Advisor From Receptor.AI

Therapies

Therapies FDA Specialty Pharmacies Clinical Trials

Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023

Agency IQ

SEPTEMBER 29, 2023

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA

FDA Science Regulations Production

Analysis Life Sciences Thank You What We Expect the FDA to do in December 2023

Agency IQ

DECEMBER 1, 2023

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. Prohaska, Kavita C.

FDA

FDA Science Regulations Production

Experts ousted from CDC panel warn of damage to US vaccine policy

BioPharma Drive: Drug Pricing

JULY 31, 2025

Published July 31, 2025 Delilah Alvarado Staff Reporter post share post print email license The main campus of the Centers For Disease Control and Prevention is seen on April 1, 2025 in Atlanta, Georgia. Kennedy Jr. urged alternatives to ACIP be organized to limit further degradation in vaccine guidelines.

Vaccine

Vaccine Specialty Pharmacies Pharmacy Therapies

Pharma’s wins and losses in the budget bill

BioPharma Drive: Drug Pricing

JUNE 12, 2025

Published June 12, 2025 Amy Baxter Staff Reporter post share post print email license Win McNamee via Getty Images First published on The budget bill currently under consideration in Congress is big — and it’s complicated. But the bill’s path forward is uncertain. Will Trump and the GOP make the leap?

Small Molecule

Small Molecule Packaging Therapies Pharmacy

Drug Discovery Digest

Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Redefining commercial success in specialty lite with alternative channels

Trending Sources

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

NOW AVAILABLE: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Available for Preorder: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Replimune drug rejected by FDA; Omega raises $647M biotech fund

NOW AVAILABLE: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

How Pharma-Funded Groups Lie About Personal Drug Imports

The Pharmacist in the Value-Based Care Era

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

Apples to apples: Stelara biosimilars and the fight for market share

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023

Analysis Life Sciences Thank You What We Expect the FDA to do in December 2023

Experts ousted from CDC panel warn of damage to US vaccine policy

Pharma’s wins and losses in the budget bill

Stay Connected